Investor Relations

Breakthrough Oxygenation

For a one-on-one update on Inspira’s activities

Schedule a meeting with Joe Hayon, President and Co-founder

Investment Highlights

Revolutionary early-stage extracorporeal respiratory support system designed to be administered while patients are awake and breathing spontaneously
Intended to use in non-invasive ventilation patients with acute respiratory failure to minimize the need for invasive mechanical ventilation
Initial pre-clinical studies (In-vivo) demonstrated the ART’s unique capabilities to rebalance
saturation levels in a significant manner³.
Indicators of growth in the market include the growing prevalence of chronic disorders, growing geriatric population, and the COVID-19 pandemic
3 strategic agreements for the deployment of the ART system in Europe and US. Agreement signed targets up to $386 million over a 7-year period, subject to regulatory approval.
Advisory board of leading professionals and experienced and committed management team
Frost & Sullivan best practices award - European artificial respirator technology innovation leadership award

Technology Innovation Leadership award

Inspira Technologies earns Frost & Sullivan’s 2021 Technology Innovation Leadership Award with its innovative medical technology, the ART System, that aims to create a new standard of care in respiratory care industry
“Frost & Sullivan finds Inspira’s ART™ demonstrates the company’s excellence in innovation. The device overcomes the limitations of its predecessors to deliver a less-invasive respiratory support system, aligning with the company’s mission.”
Samantha Fisher, Best Practices Research Analyst

Latest news and press releases

April 10, 2024

Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections

April 7, 2024

Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

SEC Filings

Research Coverage

Firm
Analyst
E-mail
Aegis Capital
Nathan Weinstein, CFA
nweinstein@aegiscap.com
Hunter Diamond, CFA
research@diamondequityresearch.com

Inspira Technologies is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Inspira Technologies’ performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Inspira Technologies or its management. Inspira Technologies does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Get in Touch!

    I consent to receive emails from Inspira Technologies Oxy B.H.N LTD. To request removal from the mailing list at any time, please send an email to info@inspirao2.com. You can find out about your rights and privacy choices, and how we use your information in our Privacy Policy.

    Ha-Tidhar St 2, Ra'anana, Israel

    Join Our Newsletter!

    Sign up and be the first to get notified on new updates of Inspira Technologies

      Copyright © 2018-2022 Inspira-Technologies OXY B.H.N. LTD., All rights reserved